19 May 2013
Keywords: b-ms, licenses, ns2214, anti-parkinson, drug, bristol-myers, squibb
Article | 22 January 1996
- Bristol-Myers Squibb has licensed marketing rights to NS2214, an oral
drug for Parkinson's disease developed by NeuroSearch A/S of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
29 January 1996
15 January 1996
17 May 2013
© 2013 thepharmaletter.com